GT Biopharma Gets FDA Clearance for GTB-5550 Multiple Myeloma Trials

Key Facts

1GT Biopharma received FDA clearance for an Investigational New Drug (IND) application for GTB-5550 to treat multiple myeloma.

2The company reported a proforma cash balance of approximately $11 million, providing a runway into Q3 2027.

3An update on the Phase 1 dose escalation trial for solid tumors is anticipated in Q4 2026.

In a move that highlights the ongoing clinical advancements within the micro-cap biotech sector, GT Biopharma has received FDA clearance for its Investigational New Drug (IND) application for GTB-5550. This clearance enables the company to initiate Phase 1 clinical trials for the treatment of multiple myeloma using its proprietary TriKE platform. According to reports, the trial will utilize subcutaneous administration, which is intended to extend the drug's half-life and provide a more patient-friendly alternative to previous intravenous formulations.

From a financial perspective, the company maintains a stable operational outlook with a proforma cash balance of approximately $11 million. This capital position is anticipated to provide a sufficient cash runway to fund ongoing activities into the third quarter of 2027. Management has indicated that further clinical initiations may depend on securing non-dilutive grant funding to support its research and development pipeline.

Regarding market performance, GTBP stood at $11.63 (at close September 14, 2026), having traded between a day low of $8.65 and a high of $11.98. Investors are now looking toward the fourth quarter of 2026, when the company is expected to provide a key update on its Phase 1 dose escalation trial for solid tumors, serving as a potential catalyst for the stock.